This has already been a disheartening year for research into drug treatments for dementia and Alzheimer’s disease. Negative results have been posted for phase III clinical trials of two 5-hydroxytryptamine-6 receptor (5-HT6) antagonists for the symptomatic treatment of moderate dementia;1 2 and another trial of an amyloid-beta antibody as a disease-modifying treatment in mild dementia.3 Pfizer announced that it will end its neuroscience and related dementia investments in drug development, removing a major industry partner from the field.4